Andexanet alfa versus prothrombin complex concentrate for direct anticoagulation reversal in intracranial hemorrhage: a comparative effectiveness study

Abstract Background While guidelines recommend andexanet alfa (AA) for reversing factor Xa (FXa) inhibitors, its high cost and thrombotic risk have led to off-label use of 4-factor prothrombin complex concentrate (4F-PCC), despite limited comparative data. This comparative effectiveness study evaluates AA vs. 4F-PCC for bleeding control in clinical practice. Methods We conducted a retrospective review of patients with acute intracranial hemorrhage who were on a factor Xa inhibitor and received 4F-PCC or AA. Demographics, clinical severity, hemorrhage volume, treatment timing, and discharge outcomes were compared. Primary outcomes were absolute and percent hemorrhage volume change, substantial hemorrhage growth (> 6 mL or >33%), and neurological deterioration (≥ 2-point GCS decrease or ≥4-point NIHSS increase). Data were analyzed using Wilcoxon Rank Sum, chi-squared tests, and Kaplan–Meier curves. Results Among 132 eligible patients, 43 received AA and 89 received 4F-PCC. Traumatic bleeds accounted for 64% of cases. Mean age was 78 years, and average baseline hemorrhage volume was 37 mL. Age, gender, race, and door-to-needle times did not differ between groups. AA patients had higher NIHSS (9 vs. 5, p = 0.003) and lower GCS (12 vs. 13, p = 0.03) scores on admission. Mean absolute and percent hemorrhage volume changes were similar; however, more patients on AA had substantial hemorrhage growth (43% vs. 22%, OR=2.65, p = 0.02). After adjustment for covariates, the association between AA and substantial hemorrhage expansion narrowly missed statistical significance (adjusted OR 2.29, P = 0.08). Neurological deterioration rates and thromboembolic complications were comparable. Conclusions AA was linked to a numerically higher risk of substantial intracranial hemorrhage growth than 4F-PCC, despite similar rates of neurological deterioration, thromboembolic events, and mortality. 4F-PCC may serve as a viable alternative for reversing FXa inhibitor anticoagulation in intracranial hemorrhage.

Authors

Institutions

Publication Details

Journal
European journal of medical research
Published
2026-11-13
DOI
https://doi.org/10.1186/s40001-026-05399-1
Primary Topic
Intracerebral and Subarachnoid Hemorrhage Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Andexanet alfa versus prothrombin complex concentrate for direct anticoagulation reversal in intracranial hemorrhage: a comparative effectiveness study

Stephan A. Mayer, Deepika Dilip, Gular Mammadli, Nimrod Gozum et al.
2 links
European journal of medical research
Intracerebral and Subarachnoid Hemorrhage Research
article

Andexanet alfa versus prothrombin complex concentrate for direct anticoagulation reversal in intracranial hemorrhage: a comparative effectiveness study

Stephan A. Mayer, Deepika Dilip, Gular Mammadli, Nimrod Gozum, Audrey Huang, Jenny Yang, Colleen Bond, Hemangi Rajpal, William Liu, Hasit Mehta, Nicole Davis, Hannah Young
article en

Abstract

Abstract Background While guidelines recommend andexanet alfa (AA) for reversing factor Xa (FXa) inhibitors, its high cost and thrombotic risk have led to off-label use of 4-factor prothrombin complex concentrate (4F-PCC), despite limited comparative data. This comparative effectiveness study evaluates AA vs. 4F-PCC for bleeding control in clinical practice. Methods We conducted a retrospective review of patients with acute intracranial hemorrhage who were on a factor Xa inhibitor and received 4F-PCC or AA. Demographics, clinical severity, hemorrhage volume, treatment timing, and discharge outcomes were compared. Primary outcomes were absolute and percent hemorrhage volume change, substantial hemorrhage growth (> 6 mL or >33%), and neurological deterioration (≥ 2-point GCS decrease or ≥4-point NIHSS increase). Data were analyzed using Wilcoxon Rank Sum, chi-squared tests, and Kaplan–Meier curves. Results Among 132 eligible patients, 43 received AA and 89 received 4F-PCC. Traumatic bleeds accounted for 64% of cases. Mean age was 78 years, and average baseline hemorrhage volume was 37 mL. Age, gender, race, and door-to-needle times did not differ between groups. AA patients had higher NIHSS (9 vs. 5, p = 0.003) and lower GCS (12 vs. 13, p = 0.03) scores on admission. Mean absolute and percent hemorrhage volume changes were similar; however, more patients on AA had substantial hemorrhage growth (43% vs. 22%, OR=2.65, p = 0.02). After adjustment for covariates, the association between AA and substantial hemorrhage expansion narrowly missed statistical significance (adjusted OR 2.29, P = 0.08). Neurological deterioration rates and thromboembolic complications were comparable. Conclusions AA was linked to a numerically higher risk of substantial intracranial hemorrhage growth than 4F-PCC, despite similar rates of neurological deterioration, thromboembolic events, and mortality. 4F-PCC may serve as a viable alternative for reversing FXa inhibitor anticoagulation in intracranial hemorrhage.

European journal of medical research
Westchester Medical Center (US), New York Medical College (US)
American Heart Association
Good health and well-being
Intracerebral and Subarachnoid Hemorrhage Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon